NICE issues positive guidance for Kyowa Kirin's Poteligeo

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has published positive guidance, in the form of a Final Appraisal Determination (FAD), confirming that Poteligeo (mogamulizumab) is recommended as a treatment option for adults in England and Wales with the ultra-rare blood cancers mycosis fungoides (MF) and Sézary syndrome (SS), two forms of cutaneous T-cell lymphoma (CTCL).

Developed and marketed by Japanese drugmaker Kyowa Kirin (TYO: 4151), the treatment is approved for use after two prior systemic treatments for adults living with MF and after one prior systemic therapy for adults living with SS.1

The FAD comes following a successful appeal lodged by Kyowa Kirin, Lymphoma Action, Leukaemia Care, and the UK Cutaneous Lymphoma Group (UKCLG) in response to a previous appraisal by the NICE, published on March 4, 2021, that concluded Poteligeo would not be made available on the National Health Service (NHS) in England and Wales